EA202090387A1 - Белки, связывающие nkg2d, cd16 и flt3 - Google Patents

Белки, связывающие nkg2d, cd16 и flt3

Info

Publication number
EA202090387A1
EA202090387A1 EA202090387A EA202090387A EA202090387A1 EA 202090387 A1 EA202090387 A1 EA 202090387A1 EA 202090387 A EA202090387 A EA 202090387A EA 202090387 A EA202090387 A EA 202090387A EA 202090387 A1 EA202090387 A1 EA 202090387A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flt3
proteins binding
binding nkg2d
nkg2d
proteins
Prior art date
Application number
EA202090387A
Other languages
English (en)
Inventor
Грегори П. Чан
Энн Ф. Чэунг
Уилльям Хани
Бредли М. Ланд
Бьянка Принц
Original Assignee
Драгонфлай Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Драгонфлай Терапьютикс, Инк. filed Critical Драгонфлай Терапьютикс, Инк.
Publication of EA202090387A1 publication Critical patent/EA202090387A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Описаны мультиспецифические связывающие белки, которые связывают рецептор NKG2D, CD16, и опухолеассоциированный антиген FLT3, а также фармацевтические композиции и терапевтические способы, пригодные для лечения рака.
EA202090387A 2017-07-31 2018-07-31 Белки, связывающие nkg2d, cd16 и flt3 EA202090387A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539421P 2017-07-31 2017-07-31
PCT/US2018/044610 WO2019028027A1 (en) 2017-07-31 2018-07-31 PROTEINS BINDING TO NKG2D, CD16 AND FLT3

Publications (1)

Publication Number Publication Date
EA202090387A1 true EA202090387A1 (ru) 2020-05-21

Family

ID=65233032

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090387A EA202090387A1 (ru) 2017-07-31 2018-07-31 Белки, связывающие nkg2d, cd16 и flt3

Country Status (15)

Country Link
US (1) US20200165344A1 (ru)
EP (1) EP3661554A4 (ru)
JP (2) JP2020529410A (ru)
KR (1) KR20200033302A (ru)
CN (1) CN111132698A (ru)
AU (1) AU2018309712A1 (ru)
BR (1) BR112020001972A2 (ru)
CA (1) CA3070986A1 (ru)
CO (1) CO2020001981A2 (ru)
EA (1) EA202090387A1 (ru)
IL (1) IL272374A (ru)
MA (1) MA49769A (ru)
MX (1) MX2020001257A (ru)
SG (1) SG11202000632QA (ru)
WO (1) WO2019028027A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CA3153858A1 (en) * 2019-10-15 2021-04-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and flt3
CN117580865A (zh) * 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5591712B2 (ja) * 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5944831B2 (ja) * 2009-12-23 2016-07-05 シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ 抗ｆｌｔ３抗体及びその使用方法
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
JP6628966B2 (ja) * 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
WO2015153765A1 (en) * 2014-04-01 2015-10-08 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells

Also Published As

Publication number Publication date
BR112020001972A2 (pt) 2020-08-04
WO2019028027A1 (en) 2019-02-07
MA49769A (fr) 2021-04-21
CO2020001981A2 (es) 2020-05-29
CA3070986A1 (en) 2019-02-07
IL272374A (en) 2020-03-31
AU2018309712A1 (en) 2020-02-13
EP3661554A1 (en) 2020-06-10
KR20200033302A (ko) 2020-03-27
JP2023106433A (ja) 2023-08-01
SG11202000632QA (en) 2020-02-27
MX2020001257A (es) 2020-08-17
CN111132698A (zh) 2020-05-08
US20200165344A1 (en) 2020-05-28
EP3661554A4 (en) 2021-04-21
JP2020529410A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
PH12020552229A1 (en) Il-11ra antibodies
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
MX2020008684A (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019013995A (es) Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.
EA201891788A1 (ru) Антитела к фно-альфа и их функциональные фрагменты
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
EA202190468A1 (ru) Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
CR20200623A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso